August 30, 2024
Johnson & Johnson seeks FDA approval for generalised myasthenia gravis therapy
Johnson & Johnson has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of nipocalimab, aimed at treating individuals with generalied myasthenia gravis (gMG).